Clinical trials Below are current clinical trials.14 studies in CAR-T Cell Therapy Program (open studies only). Filter this list of studies by location, status and more. A Study to Evaluate the Safety and Effectiveness of Idecabtagene Vicleucel to Treat Multiple Myeloma Rochester, Minn., Jacksonville, Fla. The purpose of this study is to evaluate the safety and effectiveness of nonconforming idecabtagene vicleucel (ide-cel) in subjects with multiple myeloma per the approved prescribing information. PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS Rochester, Minn. The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome. Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers Rochester, Minn. A Phase 1b/2, open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic or other specified digestive system cancers. A Study to Evaluate the Safety and Effectiveness of Lisocatagene Maraleucel in Patients Rochester, Minn., Jacksonville, Fla. The purpose of this study is to assess the safety of nonconforming lisocabtagene maraleucel in patients, and to assess the effectiveness of nonconforming lisocabtagene maraleucel in patients. Pagination Clinical studies PrevPrevious Page Go to page 11 Go to page 22 Request an appointment Frequently asked questionsReferrals June 15, 2024 Share on: FacebookTwitter CAR-T Cell Therapy ProgramDepartmenthomeSectionsOverviewAbout CAR-T cell therapyOur programDoctorsFrequently asked questionsClinical trialsReferrals Research: It's all about patients Show transcript for video Research: It's all about patients [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SectionsRequest an AppointmentOverviewAbout CAR-T cell therapyOur programDoctorsFrequently asked questionsClinical trialsReferrals ORG-20404311 Medical Departments & Centers CAR-T Cell Therapy Program